Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Current Assets (2020 - 2026)

Aura Biosciences filings provide 7 years of Current Assets readings, the most recent being $118.5 million for Q1 2026.

  • Quarterly Current Assets fell 11.9% to $118.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $118.5 million through Mar 2026, down 11.9% year-over-year, with the annual reading at $149.7 million for FY2025, 6.78% down from the prior year.
  • Current Assets hit $118.5 million in Q1 2026 for Aura Biosciences, down from $149.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $231.8 million in Q4 2023 and bottomed at $115.9 million in Q3 2022.
  • Average Current Assets over 5 years is $165.9 million, with a median of $166.2 million recorded in 2023.
  • The largest annual shift saw Current Assets skyrocketed 38.88% in 2022 before it plummeted 36.62% in 2025.
  • Aura Biosciences' Current Assets stood at $196.7 million in 2022, then grew by 17.84% to $231.8 million in 2023, then plummeted by 30.7% to $160.6 million in 2024, then fell by 6.78% to $149.7 million in 2025, then decreased by 20.86% to $118.5 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Current Assets are $118.5 million (Q1 2026), $149.7 million (Q4 2025), and $170.1 million (Q3 2025).